Table of Contents Table of Contents 2 Introduction 5 Diabetic Neuropathy - Overview 6 Diabetic Neuropathy - Therapeutics Development 7 Diabetic Neuropathy - Therapeutics Assessment 15 Diabetic Neuropathy - Companies Involved in Therapeutics Development 23 Diabetic Neuropathy - Drug Profiles 33 Diabetic Neuropathy - Dormant Projects 100 Diabetic Neuropathy - Discontinued Products 103 Diabetic Neuropathy - Product Development Milestones 104 Appendix 113

List of Tables Number of Products under Development for Diabetic Neuropathy, H2 2018 11 Number of Products under Development by Companies, H2 2018 13 Number of Products under Development by Universities/Institutes, H2 2018 15 Products under Development by Companies, H2 2018 16 Products under Development by Universities/Institutes, H2 2018 18 Number of Products by Stage and Target, H2 2018 20 Number of Products by Stage and Mechanism of Action, H2 2018 22 Number of Products by Stage and Route of Administration, H2 2018 24 Number of Products by Stage and Molecule Type, H2 2018 26 Diabetic Neuropathy - Pipeline by Achelios Therapeutics Inc, H2 2018 27 Diabetic Neuropathy - Pipeline by Angelini Group, H2 2018 27 Diabetic Neuropathy - Pipeline by Applied Therapeutics Inc, H2 2018 27 Diabetic Neuropathy - Pipeline by Arena Pharmaceuticals Inc, H2 2018 28 Diabetic Neuropathy - Pipeline by Bristol-Myers Squibb Co, H2 2018 29 Diabetic Neuropathy - Pipeline by Celularity Inc, H2 2018 29 Diabetic Neuropathy - Pipeline by Commence Bio Inc, H2 2018 29 Diabetic Neuropathy - Pipeline by Grifols SA, H2 2018 30 Diabetic Neuropathy - Pipeline by Grunenthal GmbH, H2 2018 30 Diabetic Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H2 2018 31 Diabetic Neuropathy - Pipeline by Kineta Inc, H2 2018 31 Diabetic Neuropathy - Pipeline by Medifron DBT Co Ltd, H2 2018 31 Diabetic Neuropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018 32 Diabetic Neuropathy - Pipeline by Neuralstem Inc, H2 2018 32 Diabetic Neuropathy - Pipeline by Omeros Corp, H2 2018 33 Diabetic Neuropathy - Pipeline by Reata Pharmaceuticals Inc, H2 2018 34 Diabetic Neuropathy - Pipeline by Relief Therapeutics Holding AG, H2 2018 34 Diabetic Neuropathy - Pipeline by Sphaera Pharma Pte Ltd, H2 2018 34 Diabetic Neuropathy - Pipeline by Syntrix Biosystems Inc, H2 2018 35 Diabetic Neuropathy - Pipeline by ViroMed Co Ltd, H2 2018 35 Diabetic Neuropathy - Pipeline by WEX Pharmaceuticals Inc, H2 2018 36 Diabetic Neuropathy - Pipeline by Yuhan Corp, H2 2018 36 Diabetic Neuropathy - Dormant Projects, H2 2018 104 Diabetic Neuropathy - Discontinued Products, H2 2018 107List of Figures Number of Products under Development for Diabetic Neuropathy, H2 2018 11 Number of Products under Development by Companies, H2 2018 12 Number of Products by Top 10 Targets, H2 2018 19 Number of Products by Stage and Top 10 Targets, H2 2018 19 Number of Products by Top 10 Mechanism of Actions, H2 2018 21 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 21 Number of Products by Routes of Administration, H2 2018 23 Number of Products by Stage and Routes of Administration, H2 2018 23 Number of Products by Molecule Types, H2 2018 25 Number of Products by Stage and Molecule Types, H2 2018 25

Achelios Therapeutics Inc Angelini Group Applied Therapeutics Inc Arena Pharmaceuticals Inc Bristol-Myers Squibb Co Celularity Inc Commence Bio Inc Grifols SA Grunenthal GmbH Immune Pharmaceuticals Inc Kineta Inc Medifron DBT Co Ltd Mitsubishi Tanabe Pharma Corp Neuralstem Inc Omeros Corp Reata Pharmaceuticals Inc Relief Therapeutics Holding AG Sphaera Pharma Pte Ltd Syntrix Biosystems Inc ViroMed Co Ltd WEX Pharmaceuticals Inc Yuhan Corp